|Articles|October 3, 2022

Monkeypox in Children: Uncommon but Potentially Concerning

With proper treatment, even the youngest sufferers can recover. Know the signs when treating potentially infected children, especially if they have environmental risk factors.


The vast majority of the more than 25,000 confirmed monkeypox cases in the 2022 US outbreak have occurred in adults, particularly men who have sex with men. Nevertheless, experts say that anyone in close physical contact with an infected person can contract the virus, including children. As of September 23, 27 confirmed monkeypox cases have occurred in children aged 15 and younger. Nationally, case counts peaked in August, with a high of 736 cases reported by the CDC on August 22; case numbers have dropped off somewhat, with 107 reported on September 28.

A recent case highlights the infection’s trajectory in an infant. As reported in the CDC’s September 19, 2022 Morbidity and Mortality Weekly Report (MMWR), Florida emergency room staff saw a baby less than 2 months old who presented with a raised red rash on its arms, legs, and trunk. The rash had appeared 5 days earlier. After receiving negative test results for bacteria, varicella, herpes simplex, and HIV, the infant was released. Two days later, the infant returned; the rash had worsened and now was comprised of multiple papulovesicular lesions, many of which had small, dimple-like indentations in the middle. A lesion on an arm had been scratched, leading to a diagnosis of secondary bacterial cellulitis.

The infant was admitted to the hospital and started on intravenous antibiotics. In the days following, the lesions continued to spread. They now covered the baby’s back, face, bottoms of the feet, and eyelid, and they became pustular. At this point, swabs revealed Orthopoxvirus DNA and Clade II Monkeypox virus DNA, and the baby was given oral tecovirimat, vaccinia immune globulin intravenous, and prophylactic trifluridine eye drops to ward off potential complications from the eyelid lesion. There were no further complications, and the infant recovered.

Although the infant had not traveled, spent time in a childcare facility, or had any infections in the weeks preceding the diagnosis, 1 of the baby’s 4 caregivers had participated in activities deemed high risk for monkeypox and in fact had experienced blood in the urine, fever, and a rash 3 weeks before the infant exhibited a rash. After the baby was hospitalized, the caregiver received a positive Orthopox DNA test.

While monkeypox in children in general looks much like monkeypox in adults, CDC experts caution that children may be more likely to get sicker. In their report, the authors reference a 2003 study of 34 subjects who became ill with monkeypox after pet prairie dogs were transported with infected rodents. Of the 5 subjects who were severely ill, 2 were young children who received treatment in the intensive care unit. The authors acknowledge it is difficult to determine whether their admittance to intensive care reflects the severity of their illness or simply a different standard of care. And it’s important to note the study’s small size, as its findings might not be replicated in a larger trial.

Clinicians who see pediatric patients with rashes that spread, resemble pimples or blisters, and are itchy and scabbed over should consider monkeypox as a diagnosis, especially if other factors are present that make it more likely, such as close contact with someone who has the disease. Although treatment regimens should reflect individual patients, young children–especially those with eczema or similar skin conditions or who are otherwise immunocompromised–may be at risk of more severe disease. As with adults, tecovirimat is the first-line medication of choice.

For children who have been exposed to monkeypox, experts advise practitioners to consider a post-exposure prophylaxis regimen. This may include the JYNNEOS vaccine (available under an Emergency Use Authorization for people below the age of 18), the administration of immune globulin, or the use of antivirals.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.